Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00604919 | Prostate | BPH | regulation of cell projection assembly | 51/3107 | 188/18723 | 1.73e-04 | 1.48e-03 | 51 |
GO:00070525 | Prostate | BPH | mitotic spindle organization | 36/3107 | 120/18723 | 1.83e-04 | 1.54e-03 | 36 |
GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
GO:00518946 | Prostate | BPH | positive regulation of focal adhesion assembly | 13/3107 | 28/18723 | 2.22e-04 | 1.78e-03 | 13 |
GO:000195410 | Prostate | BPH | positive regulation of cell-matrix adhesion | 21/3107 | 58/18723 | 2.44e-04 | 1.94e-03 | 21 |
GO:012003210 | Prostate | BPH | regulation of plasma membrane bounded cell projection assembly | 50/3107 | 186/18723 | 2.53e-04 | 2.00e-03 | 50 |
GO:000974915 | Prostate | BPH | response to glucose | 55/3107 | 212/18723 | 3.42e-04 | 2.55e-03 | 55 |
GO:00072547 | Prostate | BPH | JNK cascade | 45/3107 | 167/18723 | 4.74e-04 | 3.39e-03 | 45 |
GO:00310998 | Prostate | BPH | regeneration | 51/3107 | 198/18723 | 6.58e-04 | 4.45e-03 | 51 |
GO:00070516 | Prostate | BPH | spindle organization | 48/3107 | 184/18723 | 6.91e-04 | 4.60e-03 | 48 |
GO:19021154 | Prostate | BPH | regulation of organelle assembly | 48/3107 | 186/18723 | 8.91e-04 | 5.72e-03 | 48 |
GO:00108124 | Prostate | BPH | negative regulation of cell-substrate adhesion | 22/3107 | 68/18723 | 1.04e-03 | 6.52e-03 | 22 |
GO:00463287 | Prostate | BPH | regulation of JNK cascade | 36/3107 | 133/18723 | 1.52e-03 | 8.95e-03 | 36 |
GO:00435478 | Prostate | BPH | positive regulation of GTPase activity | 61/3107 | 255/18723 | 1.58e-03 | 9.23e-03 | 61 |
GO:00313457 | Prostate | BPH | negative regulation of cell projection organization | 47/3107 | 186/18723 | 1.61e-03 | 9.33e-03 | 47 |
GO:000167810 | Prostate | BPH | cellular glucose homeostasis | 44/3107 | 172/18723 | 1.71e-03 | 9.87e-03 | 44 |
GO:007133310 | Prostate | BPH | cellular response to glucose stimulus | 39/3107 | 151/18723 | 2.52e-03 | 1.35e-02 | 39 |
GO:00716928 | Prostate | BPH | protein localization to extracellular region | 82/3107 | 368/18723 | 2.59e-03 | 1.39e-02 | 82 |
GO:00109776 | Prostate | BPH | negative regulation of neuron projection development | 36/3107 | 137/18723 | 2.64e-03 | 1.41e-02 | 36 |
GO:00093069 | Prostate | BPH | protein secretion | 80/3107 | 359/18723 | 2.89e-03 | 1.52e-02 | 80 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4 | SNV | Missense_Mutation | novel | c.3131A>G | p.Asn1044Ser | p.N1044S | P27816 | protein_coding | deleterious(0.01) | possibly_damaging(0.641) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
MAP4 | SNV | Missense_Mutation | | c.71A>G | p.Asp24Gly | p.D24G | P27816 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4 | insertion | In_Frame_Ins | novel | c.3410_3411insCTTACTGTCCAAAACTACAAGGACAGTGACAGTTCTGACAGG | p.Gln1137delinsHisLeuLeuSerLysThrThrArgThrValThrValLeuThrGly | p.Q1137delinsHLLSKTTRTVTVLTG | P27816 | protein_coding | | | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP4 | insertion | Nonsense_Mutation | novel | c.2692_2693insACTGCATATAGTGATGGAGAAAGATCACAGT | p.Pro898HisfsTer4 | p.P898Hfs*4 | P27816 | protein_coding | | | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
MAP4 | SNV | Missense_Mutation | novel | c.1241N>T | p.Ser414Leu | p.S414L | P27816 | protein_coding | deleterious(0) | possibly_damaging(0.656) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
MAP4 | SNV | Missense_Mutation | novel | c.2122N>G | p.Gln708Glu | p.Q708E | P27816 | protein_coding | deleterious(0.04) | benign(0.328) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4 | SNV | Missense_Mutation | | c.3155G>A | p.Gly1052Glu | p.G1052E | P27816 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4 | SNV | Missense_Mutation | | c.2968G>T | p.Gly990Trp | p.G990W | P27816 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MU-A5YI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MAP4 | SNV | Missense_Mutation | novel | c.2544G>C | p.Lys848Asn | p.K848N | P27816 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
MAP4 | SNV | Missense_Mutation | novel | c.478G>T | p.Ala160Ser | p.A160S | P27816 | protein_coding | tolerated(0.13) | benign(0.039) | TCGA-5M-AATE-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |